In the last years, immunotherapy has emerged as therapeutic option of choice for several different advanced diseases, especially in the oncology field. Many drugs have received regulatory clearance both in the EU and US for melanoma, lung, bladder, renal and oropharyngeal cancers among others. In turn, the tools to asses therapy efficacy and response have evolved to better understand the disease progression and the effects of these new therapies. This is the case for example of the RECIST criteria, developed originally for chemotherapy, that were updated with immune-related response criteria (irRC), immune-related RECIST (irRECIST), and immune RECIST (iRECIST).
Image assessment of cancerous lesions development is still the state of the art for therapy planning and follow up, but novel tools are required to improve patients management and quality of life. This Research Topic will focus on the breakthrough in imaging and image analysis approaches for immunotherapy assessment.
Topics will include, but are not limited to, the following:
- Novel imaging modalities to evaluate immunotherapy
- Quantitative image analysis
- Imaging biomarkers
- Image based response assessment
Sean Walsh have shares in the company? Radiomics. Mariaelena Occhipinti reports personal fees from Radiomics. All other Topic Editors declare no conflict of interest in relation to the Research Topic theme.
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
In the last years, immunotherapy has emerged as therapeutic option of choice for several different advanced diseases, especially in the oncology field. Many drugs have received regulatory clearance both in the EU and US for melanoma, lung, bladder, renal and oropharyngeal cancers among others. In turn, the tools to asses therapy efficacy and response have evolved to better understand the disease progression and the effects of these new therapies. This is the case for example of the RECIST criteria, developed originally for chemotherapy, that were updated with immune-related response criteria (irRC), immune-related RECIST (irRECIST), and immune RECIST (iRECIST).
Image assessment of cancerous lesions development is still the state of the art for therapy planning and follow up, but novel tools are required to improve patients management and quality of life. This Research Topic will focus on the breakthrough in imaging and image analysis approaches for immunotherapy assessment.
Topics will include, but are not limited to, the following:
- Novel imaging modalities to evaluate immunotherapy
- Quantitative image analysis
- Imaging biomarkers
- Image based response assessment
Sean Walsh have shares in the company? Radiomics. Mariaelena Occhipinti reports personal fees from Radiomics. All other Topic Editors declare no conflict of interest in relation to the Research Topic theme.
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
